Get the Stockscreener App
23.20
0.72%
0.125
Xencor Inc stock is traded at $23.20, with a volume of 340.83K.
It is up +0.72% in the last 24 hours and up +6.68% over the past month.
Xencor Inc is a clinical-stage biopharmaceutical company based in the United States. It focuses on discovering and developing engineered monoclonal antibody and other protein therapeutics to treat severe and life-threatening diseases such with unmet medical needs. The company uses its XmAb technology platform to create antibody product candidates such as XmAb5871 and XmAb7195. It also has a few pre-clinical stage candidates in its portfolio such as XmAb14045, XmAb662 among others. It earns its revenue from research and development collaborations and licenses of its internally developed drug candidates.
See More
Previous Close:
$23.07
Open:
$23.2
24h Volume:
340.83K
Relative Volume:
0.68
Market Cap:
$1.63B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-10.84
EPS:
-2.14
Net Cash Flow:
$23.50M
1W Performance:
-0.32%
1M Performance:
+6.68%
6M Performance:
+0.89%
1Y Performance:
+20.89%
1-Day Range:
$22.75
$23.44
1-Week Range:
$22.60
$24.04
52-Week Range:
$15.31
$26.84
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| XNCR | 23.23 | 1.63B | 133.62M | -177.37M | 23.50M | -2.14 |
| VRTX | 467.02 | 119.83B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 759.96 | 83.28B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 564.96 | 33.74B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 231.19 | 30.38B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.53 | 24.08B | 3.30B | -501.07M | 1.03B | 11.54 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Wall Street Analysts Believe Xencor (XNCR) Could Rally 53.53%: Here's is How to Trade - Yahoo Finance
(XNCR) Proactive Strategies - Stock Traders Daily
Xencor (XNCR)'s Technical Outlook is Bright After Key Golden Cross - MSN
EcoR1 Capital, LLC Increases Stake in Xencor Inc - GuruFocus.com
US Bancorp DE Reduces Stock Position in Xencor, Inc. (NASDAQ:XNCR) - Defense World
Xencor CEO Dahiyat Bassil sells shares worth $80,841 - Investing.com
Xencor executive sells shares worth $1.6 million - Investing.com India
Xencor executive sells shares worth $1.6 million By Investing.com - Investing.com Nigeria
PRIMECAP Management Bolsters Stake in Xencor Inc - GuruFocus.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead - Investing.com
Xencor's SWOT analysis: biotech stock faces pivotal year ahead By Investing.com - Investing.com UK
Xencor, Inc. (NASDAQ:XNCR) Analysts Just Slashed Next Year's Revenue Estimates By 14% - Yahoo Finance UK
Xencor, Inc. (NASDAQ:XNCR) Shares Sold by Creative Planning - Defense World
Xencor’s (XNCR) “Outperform” Rating Reiterated at BMO Capital Markets - Defense World
Xencor (NASDAQ:XNCR) Given New $28.00 Price Target at JPMorgan Chase & Co. - Defense World
Xencor (NASDAQ:XNCR) Given Outperform Rating at Wedbush - Defense World
What is Wedbush’s Forecast for Xencor FY2024 Earnings? - Defense World
Leerink Partnrs Increases Earnings Estimates for Xencor - Defense World
Leerink Partnrs Brokers Lift Earnings Estimates for Xencor - MarketBeat
What is Wedbush's Forecast for Xencor FY2024 Earnings? - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Just Reported And Analysts Have Been Cutting Their Estimates - Simply Wall St
Xencor (NASDAQ:XNCR) Receives "Outperform" Rating from BMO Capital Markets - MarketBeat
Xencor shares target raised, rating held on pipeline progress By Investing.com - Investing.com Canada
Xencor shares target raised, rating held on pipeline progress - Investing.com
Xencor (NASDAQ:XNCR) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Xencor (NASDAQ:XNCR) shareholders are up 7.9% this past week, but still in the red over the last three years - Simply Wall St
Xencor Reports Third Quarter 2024 Financial Results - BioSpace
Xencor Inc earnings beat by $0.27, revenue fell short of estimates - Investing.com Canada
Xencor (XNCR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Xencor: Q3 Earnings Snapshot - San Antonio Express-News
Trading (XNCR) With Integrated Risk Controls - Stock Traders Daily
Xencor Doses First Subject in Phase 1/2 Study of XmAb®942 in Development for Patients with Inflammatory Bowel Disease - BioSpace
Please Don’t Call Me a ‘Genus’: The High Bar for Section 112 in the Unpredictable Arts as Illustrated by In re Xencor - IPWatchdog.com
942 in Development for Patients with Inflammatory Bowel Disease - Business Wire
Does Xencor (XNCR) Have the Potential to Rally 68.16% as Wall Street Analysts Expect? - Yahoo Finance
Xencor (XNCR) Expected to Beat Earnings Estimates: Should You Buy? - MSN
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of "Buy" by Brokerages - MarketBeat
Xencor, Inc. (NASDAQ:XNCR) Given Average Rating of “Buy” by Analysts - Defense World
How to Take Advantage of moves in (XNCR) - Stock Traders Daily
Essex LLC Takes Position in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Creative Planning Sells 3,356 Shares of Xencor, Inc. (NASDAQ:XNCR) - Defense World
State Street Corp's Strategic Reduction in Xencor Inc Holdings - GuruFocus.com
Wall Street Analysts Predict a 67.2% Upside in Xencor (XNCR): Here's What You Should Know - Yahoo Finance
(XNCR) Pivots Trading Plans and Risk Controls - Stock Traders Daily
AQR Capital Management LLC Invests $753,000 in Xencor, Inc. (NASDAQ:XNCR) - MarketBeat
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Xencor Inc Stock (XNCR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dahiyat Bassil I | PRESIDENT & CEO |
Nov 13 '24 |
Sale |
24.02 |
3,366 |
80,842 |
352,615 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Nov 11 '24 |
Option Exercise |
15.69 |
68,684 |
1,077,652 |
268,788 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Nov 12 '24 |
Option Exercise |
15.69 |
12,774 |
200,424 |
212,878 |
| Desjarlais John R | SR. VICE PRESIDENT & CSO |
Nov 11 '24 |
Sale |
23.48 |
68,684 |
1,612,639 |
200,104 |
3.39%
0.01%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):